Filing Flows › Generate Biomedicines (GENB) › Q1 2026 › vs Q1 2025
Generate Biomedicines (GENB) Q1 2026 vs Q1 2025 (year over year)
Generate Biomedicines's revenue fell $1.6M (-18%) from $8.8M in Q1 2025 to $7.2M in Q1 2026.
Generate Biomedicines, Q1 2026: revenue $7.2M (-18% year over year), operating margin -887.5%, net loss $61.7M, operating cash flow −$80.4M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $7.2M | $8.8M | −$1.6M | -18% |
| Other income, net | $2.4M | $3.9M | −$1.5M | -38% |
| Net loss | $61.7M | $44.3M | $17.4M | +39% |
| Costs & expenses | $71.4M | $57.0M | $14.3M | +25% |
| Operating costs | $71.3M | $57.0M | $14.4M | +25% |
| Income tax | $28K | $56K | −$28K | -50% |
| Research & development | $57.8M | $46.8M | $11.0M | +23% |
| General & admin | $13.5M | $10.1M | $3.4M | +33% |
| Operating cash sources | $90.1M | $61.3M | $28.7M | +47% |
| Depreciation & amortization | $3.3M | $3.4M | −$141K | -4% |
| Share-based compensation | $6.4M | $4.7M | $1.7M | +35% |
| Cash used in operations | $80.4M | $53.2M | $27.2M | +51% |
| Net loss absorbed | $61.7M | $44.3M | $17.4M | +39% |
| Working capital & other | $28.3M | $17.0M | $11.3M | +67% |
Questions
How much did Generate Biomedicines's revenue grow year over year in Q1 2026?
Generate Biomedicines's revenue fell $1.6M (-18%) from $8.8M in Q1 2025 to $7.2M in Q1 2026.